[go: up one dir, main page]

CO2018004665A2 - Compuestos oxadiazoespíricos - Google Patents

Compuestos oxadiazoespíricos

Info

Publication number
CO2018004665A2
CO2018004665A2 CONC2018/0004665A CO2018004665A CO2018004665A2 CO 2018004665 A2 CO2018004665 A2 CO 2018004665A2 CO 2018004665 A CO2018004665 A CO 2018004665A CO 2018004665 A2 CO2018004665 A2 CO 2018004665A2
Authority
CO
Colombia
Prior art keywords
compounds
oxadiazoespiric
pharmacological activity
oxadiazaspiric
addiction
Prior art date
Application number
CONC2018/0004665A
Other languages
English (en)
Inventor
Marina Virgili-Bernado
Carmen Almansa-Rosales
Carlos Alegret-Molina
Original Assignee
Esteve Labor Dr
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Esteve Labor Dr filed Critical Esteve Labor Dr
Publication of CO2018004665A2 publication Critical patent/CO2018004665A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/10—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5386—1,4-Oxazines, e.g. morpholine spiro-condensed or forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Addiction (AREA)
  • Neurology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Hydrogenated Pyridines (AREA)

Abstract

La presente invención se refiere a compuestos que tienen actividad farmacológica hacia el receptor sigma () y, más en particular, a compuestos oxadiazaespíricos que tienen dicha actividad farmacológica, a procedimientos de preparación de tales compuestos, a composiciones farmacéuticas que los comprenden y a su uso en terapia, en particular, contra el abuso y la adicción a las drogas.
CONC2018/0004665A 2015-11-16 2018-04-30 Compuestos oxadiazoespíricos CO2018004665A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP15382566 2015-11-16
PCT/EP2016/001907 WO2017084752A1 (en) 2015-11-16 2016-11-15 Oxadiazaspiro compounds for the treatment of drug abuse and addiction

Publications (1)

Publication Number Publication Date
CO2018004665A2 true CO2018004665A2 (es) 2018-07-19

Family

ID=54707728

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2018/0004665A CO2018004665A2 (es) 2015-11-16 2018-04-30 Compuestos oxadiazoespíricos

Country Status (30)

Country Link
US (2) US10927128B2 (es)
EP (1) EP3377500B1 (es)
JP (1) JP6884974B2 (es)
KR (2) KR20180080327A (es)
CN (1) CN108349999A (es)
AR (1) AR106697A1 (es)
AU (1) AU2016356488B2 (es)
CA (1) CA3002286A1 (es)
CO (1) CO2018004665A2 (es)
DK (1) DK3377500T3 (es)
ES (1) ES2932000T3 (es)
HR (1) HRP20221343T1 (es)
HU (1) HUE060275T2 (es)
IL (1) IL259035B (es)
LT (1) LT3377500T (es)
MA (1) MA43250B1 (es)
MX (1) MX384637B (es)
MY (1) MY193423A (es)
PH (1) PH12018500814A1 (es)
PL (1) PL3377500T3 (es)
PT (1) PT3377500T (es)
RS (1) RS63734B1 (es)
SG (1) SG11201803153RA (es)
SI (1) SI3377500T1 (es)
SM (1) SMT202200460T1 (es)
TN (1) TN2018000122A1 (es)
TW (1) TWI756196B (es)
UA (1) UA123775C2 (es)
WO (1) WO2017084752A1 (es)
ZA (1) ZA201802845B (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE060275T2 (hu) 2015-11-16 2023-02-28 Esteve Pharmaceuticals Sa Hatóanyaggal való visszaélés és addikció kezelésére alkalmas oxadiazaspiro-vegyületek
WO2020157026A1 (en) * 2019-01-28 2020-08-06 Esteve Pharmaceuticals, S.A. Hydroxylated derivatives of 1-oxa-4,9-diazaspiro undecane compounds having multimodal activity against pain
US20250002503A1 (en) 2021-09-20 2025-01-02 Esteve Pharmaceuticals, S.A. Oxadiazaspiro compounds for use in the treatment of motoneuron degeneration or in neuroprotection
WO2024105225A1 (en) 2022-11-18 2024-05-23 Universitat De Barcelona Synergistic combinations of a sigma receptor 1 (s1r) antagonist and a soluble epoxide hydrolase inhibitor (sehi) and their use in the treatment of pain

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4244961A (en) * 1978-10-26 1981-01-13 Syntex (U.S.A.) Inc. 1-Oxa-3,8-diazaspiro[4.5]decan-2-ones antihypertensive agents
US4332804A (en) 1981-03-23 1982-06-01 Syntex (U.S.A.) Inc. 9-[2-(3-Indolyl)ethyl]-1oxa-4,9-diazaspiro[5.5]undecan-3-ones
US4353901A (en) * 1981-10-19 1982-10-12 Syntex (U.S.A.) Inc. 9-(1,4-Benzodioxan-2-ylalkyl and hydroxyalkyl)-1-oxa-4,9-diazaspiro[5.5]undecan-3-ones
US4353900A (en) 1981-10-19 1982-10-12 Syntex (U.S.A.) Inc. 9-(Arylalkyl or aroylalkyl)-1-oxa-4,9-diazaspiro(5.5)undecan-3-ones
US6114541A (en) 1997-03-10 2000-09-05 Hoffmann-La Roche Inc. Method for the preparation of α-Bromo-Lactam derivatives
AU2005211499A1 (en) * 2004-02-10 2005-08-18 F. Hoffmann-La Roche Ag Chemokine CCR5 receptor modulators
DE602005025979D1 (de) 2004-03-03 2011-03-03 Vital Health Sciences Pty Ltd Alkaloid-formulierungen
EP1634873A1 (en) 2004-08-27 2006-03-15 Laboratorios Del Dr. Esteve, S.A. Sigma receptor inhibitors
US7951816B2 (en) * 2004-08-27 2011-05-31 Ono Pharmaceutical Co., Ltd. Compound containing basic group and use thereof
CN101228127B (zh) 2005-05-30 2012-05-16 Msdk.K.公司 哌啶衍生物
CN101203567A (zh) * 2005-06-07 2008-06-18 西巴特殊化学品控股有限公司 抗刮擦聚烯烃
DE102005030051A1 (de) 2005-06-27 2006-12-28 Grünenthal GmbH Substituierte 1-Oxa-3,8-diazaspiro[4,5]-decan-2-on-Verbindungen und deren Verwendung zur Herstellung von Arzneimitteln
CN103382176A (zh) 2005-10-19 2013-11-06 格吕伦塔尔有限公司 新颖的辣椒素受体配体和它们用于生产药物的用途
PL1961744T3 (pl) 2005-11-18 2013-09-30 Ono Pharmaceutical Co Związek zawierający grupę zasadową oraz jego zastosowanie
EP1829869A1 (en) 2006-03-02 2007-09-05 Laboratorios Del Dr. Esteve, S.A. 4,5,6,7-Tetrahydrobenzo[b]thiophene derivatives and their use as sigma receptor ligands
EP1847542A1 (en) 2006-04-21 2007-10-24 Laboratorios del Dr. Esteve S.A. Spiro[benzopyran] or spiro[benzofuran] derivatives which inhibit the sigma receptor
US8877779B2 (en) 2007-03-01 2014-11-04 Mitsubishi Tanabe Pharma Corporation Benzimidazole compound and pharmaceutical use thereof
EP1982714A1 (en) 2007-04-16 2008-10-22 Laboratorios del Dr. Esteve S.A. Pyrano-pyrazole-amines
EP2020414A1 (en) * 2007-06-20 2009-02-04 Laboratorios del Dr. Esteve S.A. spiro[piperidine-4,4'-thieno[3,2-c]pyran] derivatives and related compounds as inhibitors of the sigma receptor for the treatment of psychosis
EP2197876A1 (en) 2007-08-29 2010-06-23 Glaxosmithkline LLC Thiazole and oxazole kinase inhibitors
EP2070933A1 (en) 2007-12-07 2009-06-17 Laboratorios del Dr. Esteve S.A. Tricyclic triazolic compounds
PL2242759T3 (pl) 2008-02-06 2013-06-28 Astrazeneca Ab Związki
EP2108643A1 (en) * 2008-04-10 2009-10-14 Laboratorios Del. Dr. Esteve, S.A. 4-methyl-4, 5-dihydro-1H-pyrazole-3-carboxamide useful as a cannabinoid CB1 neutral antagonist
GB201016912D0 (en) * 2010-10-07 2010-11-24 Astrazeneca Ab Novel combination
EP2686325B1 (en) 2011-03-14 2016-12-14 Vertex Pharmaceuticals Incorporated Morpholine-spirocyclic piperidine amides as modulators of ion channels
GB201107985D0 (en) 2011-05-13 2011-06-29 Astrazeneca Ab Process
WO2013052716A1 (en) * 2011-10-07 2013-04-11 Glaxosmithkline Llc Fatty acid synthase inhibitors
WO2013115294A1 (ja) * 2012-01-31 2013-08-08 東レ株式会社 ジアザスピロウレア誘導体及びその医薬用途
EP3027625B1 (en) 2013-07-31 2018-05-30 Merck Sharp & Dohme Corp. Spiro-fused derivatives of piperidine useful for the treatment of inter alia hypertension and acute or chronic heart failure
TW201615642A (zh) 2014-06-02 2016-05-01 伊史帝夫博士實驗室股份有限公司 具有多重模式抗疼痛活性的１－氧雜－４，９－二氮雜螺十一烷化合物之醯胺衍生物
TWI685497B (zh) * 2014-06-02 2020-02-21 西班牙商伊史帝夫製藥公司 具有多重模式抗疼痛活性的１-氧雜-４,９-二氮雜螺十一烷化合物之烷基衍生物
TW201615643A (zh) * 2014-06-02 2016-05-01 伊史帝夫博士實驗室股份有限公司 具有多重模式抗疼痛活性之１－氧雜－４，９－二氮雜螺十一烷化合物之烷基與芳基衍生物
US10513518B2 (en) * 2015-01-29 2019-12-24 Merck Sharp & Dohme Corp. Inhibitors of the renal outer medullary potassium channel
HUE060275T2 (hu) 2015-11-16 2023-02-28 Esteve Pharmaceuticals Sa Hatóanyaggal való visszaélés és addikció kezelésére alkalmas oxadiazaspiro-vegyületek

Also Published As

Publication number Publication date
US20180327422A1 (en) 2018-11-15
MA43250B1 (fr) 2022-12-30
RU2018120748A (ru) 2019-12-05
JP2018533598A (ja) 2018-11-15
WO2017084752A1 (en) 2017-05-26
DK3377500T3 (da) 2022-11-21
BR112018009279A2 (pt) 2018-11-06
EP3377500B1 (en) 2022-10-19
MY193423A (en) 2022-10-12
RU2018120748A3 (es) 2020-02-07
KR20250069710A (ko) 2025-05-19
RS63734B1 (sr) 2022-12-30
PL3377500T3 (pl) 2023-01-23
CA3002286A1 (en) 2017-05-26
ES2932000T3 (es) 2023-01-09
AR106697A1 (es) 2018-02-07
SI3377500T1 (sl) 2023-02-28
US20210115062A1 (en) 2021-04-22
PH12018500814A1 (en) 2018-10-29
IL259035B (en) 2021-06-30
PT3377500T (pt) 2022-11-25
MA43250A (fr) 2021-04-14
BR112018009279A8 (pt) 2019-02-26
EP3377500A1 (en) 2018-09-26
SG11201803153RA (en) 2018-06-28
HUE060275T2 (hu) 2023-02-28
HRP20221343T1 (hr) 2022-12-23
SMT202200460T1 (it) 2023-01-13
AU2016356488B2 (en) 2020-10-22
TWI756196B (zh) 2022-03-01
IL259035A (en) 2018-06-28
JP6884974B2 (ja) 2021-06-09
MX2018005439A (es) 2018-11-09
MX384637B (es) 2025-03-14
US11649248B2 (en) 2023-05-16
TN2018000122A1 (en) 2019-10-04
KR20180080327A (ko) 2018-07-11
US10927128B2 (en) 2021-02-23
CN108349999A (zh) 2018-07-31
UA123775C2 (uk) 2021-06-02
LT3377500T (lt) 2022-12-12
TW201731854A (zh) 2017-09-16
AU2016356488A1 (en) 2018-05-10
ZA201802845B (en) 2021-10-27

Similar Documents

Publication Publication Date Title
DOP2019000005A (es) 3-metil pirazinas 2,5-disustituidas y 3-metil pirazinas 2,5,6-trisustituidas como inhibidores alostéricos de shp2
CO2017001994A2 (es) Compuestos activos hacia bromodominios
MX2018003388A (es) Agonistas del receptor farnesoide x y usos de los mismos.
MX2020004467A (es) Metodos para el tratamiento o la prevencion del asma mediante la administracion de antagonista de il-4r.
CL2014003444A1 (es) Compuestos derivados tienopirimidina; proceso de preparacion; composicion farmaceutica que los comprende; combinacion farmaceutica; uso en el tratamiento de canceres y enfermedades autoinmunes.
CR20160518A (es) Compuestos para tratar atrofia muscular espinal
MX2021008113A (es) Composiciones farmaceuticas que comprenden un antagonista de il-4r para usarse en el tratamiento del asma.
CR20150326A (es) Inhibidores de autotaxina
MX2016004340A (es) Compuestos heterociclicos y usos de los mismos.
MX379193B (es) Composiciones en solucion solida y su uso en inflamacion cronica.
DOP2016000226A (es) Compuestos de isoindolinona como moduladores de gpr119 para el tratamiento de diabetes, obesidad, dislipidemia y trastornos relacionados
MX387235B (es) Derivados de pirazolopiridina y su uso en terapia
CU20160020A7 (es) Derivados de imidazoquinolinas sustituidas inhibidores de mek para el tratamiento del cáncer
MX2016016583A (es) Derivados de indolizina como inhibidores de fosfoinositido-3 cinasas.
BR112017005231A2 (pt) formulações eutéticas de cloridrato de ciclobenzaprina
MD20170048A2 (ro) Formulare pe bază de acetat de abirateronă şi procedee de utilizare a acesteia
MX2015012833A (es) Composiciones antibioticas de ceftolozano.
PH12016500978A1 (en) Piperazine derivatives having multimodal activity against pain
CR20160290A (es) Inhibidores tetracíclicos de autotaxina
CL2015000039A1 (es) Derivados estra-1,3,5(10),16-tetraeno-3-sustituidos, preparaciones farmacéuticas que los comprenden y su uso en la preparación de medicamentos para tratar la endometriosis.
MX2016006604A (es) Derivados de piperidina con actividad multimodal contra el dolor.
MX2017013137A (es) Derivados de cromeno como inhibidores de las fosfoinositido-3-cina sas.
BR112018071370A2 (pt) composições farmacêuticas orais de mesalazina
CO2018004665A2 (es) Compuestos oxadiazoespíricos
MX2015009277A (es) Formas de dosificacion y usos terapauticos de l-4-cloro quinurenina.